| Estrogen receptor β in Alzheimer’s disease: From mechanisms to therapeutics L Zhao, SK Woody, A Chhibber Ageing research reviews 24, 178-190, 2015 | 105 | 2015 |
| Estrogen receptor β deficiency impairs BDNF–5-HT2A signaling in the hippocampus of female brain: A possible mechanism for menopausal depression A Chhibber, SK Woody, MAK Rumi, MJ Soares, L Zhao Psychoneuroendocrinology 82, 107-116, 2017 | 102 | 2017 |
| Global economic burden of attention-deficit/hyperactivity disorder: a systematic review A Chhibber, AH Watanabe, C Chaisai, SK Veettil, N Chaiyakunapruk Pharmacoeconomics 39, 399-420, 2021 | 56 | 2021 |
| Brain clusterin protein isoforms and mitochondrial localization SK Herring, HJ Moon, P Rawal, A Chhibber, L Zhao Elife 8, e48255, 2019 | 49 | 2019 |
| ERβ and ApoE isoforms interact to regulate BDNF–5-HT2A signaling and synaptic function in the female brain A Chhibber, L Zhao Alzheimer's research & therapy 9, 1-10, 2017 | 28 | 2017 |
| Statin use and mortality in rheumatoid arthritis: an incident user cohort study A Chhibber, S Hansen, J Biskupiak Journal of Managed Care & Specialty Pharmacy 27 (3), 296-305, 2021 | 16 | 2021 |
| Strategies to minimize inequity in COVID-19 vaccine access in the US: implications for future vaccine rollouts A Chhibber, A Kharat, K Duong, RE Nelson, MH Samore, FA Wilson, ... The Lancet Regional Health–Americas 7, 2022 | 9 | 2022 |
| Assessment of health equity consideration in masking/PPE policies to contain COVID-19 using PROGRESS-plus framework: a systematic review A Chhibber, A Kharat, D Kneale, V Welch, M Bangpan, N Chaiyakunapruk BMC Public Health 21, 1-25, 2021 | 7 | 2021 |
| Comparative safety and efficacy of therapeutic options in resectable and advanced/metastatic pancreatic cancer: a systematic review and indirect comparison A Kharat, M Brendle, A Chhibber, N Chaiyakunapruk, J Biskupiak Oncology Research and Treatment 44 (9), 476-484, 2021 | 7 | 2021 |
| Real-world outcomes with novel therapies in R/R DLBCL. Jennifer Leigh Crombie, Monika P. Jun, Tongsheng Wang, Alex Mutebi, Anthony ... ASCO 41 (41:16_suppl), 7552-7552, 2023 | 5* | 2023 |
| Angiotensin‐converting enzyme inhibitors reduce community‐acquired pneumonia hospitalization and mortality DP Alexander, NA Nickman, A Chhibber, GJ Stoddard, JE Biskupiak, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 42 (12 …, 2022 | 5 | 2022 |
| Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma JL Crombie, M Jun, T Wang, A Mutebi, A Wang, A Chhibber, R Kamalakar, ... Leukemia & Lymphoma 65 (11), 1623-1633, 2024 | 1 | 2024 |
| CLO22-090: Patient Characteristics, Treatment Patterns, and Clinical Outcomes of Patients With Advanced HER2-Low Breast Cancer AH Watanabe, C Willis, M Pavilack-Kirker, C Lam, L Park, S Mehta, ... Journal of the National Comprehensive Cancer Network 20 (3.5), CLO22-090 …, 2022 | 1 | 2022 |
| PMH20 economic burden of attention-deficit/hyperactivity disorder (ADHD): a global systematic review A Chhibber, AH Watanabe, C Chaisai, S Veettil, N Chaiyakunapruk Value in Health 23, S203, 2020 | 1 | 2020 |
| Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: A retrospective claims analysis (2015–2020) MP Jun, A Mutebi, A Chhibber, C Liang, A Keshishian, A Wang, ... Journal of Medical Economics 27 (1), 1157-1167, 2024 | | 2024 |
| Patient characteristics and treatment patterns of patients with locally advanced or metastatic HER2-low breast cancer, a single site descriptive study C Willis, CJ Tan, A Chhibber, AH Watanabe, C Lam, S Mehta, J Kwong, ... Breast Cancer Research and Treatment 208 (3), 619-630, 2024 | | 2024 |
| Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals A Sureda, SE Adam, S Yang, E Griffin, J Baker, K Johnston, FR Navarro, ... Future Oncology 20 (36), 2855-2868, 2024 | | 2024 |
| Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients … J Munoz, AC Rosenthal, A Ip, JM Darrah, T Wang, G Zhang, A Mutebi, ... Blood 144, 7760, 2024 | | 2024 |
| Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) JN Allan, CP Fox, GS Nowakowski, PA Riedell, TJ Phillips, AW Wang, ... Blood 144, 2349, 2024 | | 2024 |
| Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell … A Ip, J Munoz, AC Rosenthal, JM Darrah, T Wang, G Zhang, A Mutebi, ... Blood 144, 7757, 2024 | | 2024 |
